Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 60

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 60
---
MedSurg% of net salesCardiovascular% of net salesTotalNet sales of reportable segments$1,598 $3,133 $4,731 Impact of foreign currency fluctuations(69)Total net sales4,663 Segment expenses:Cost of products sold435 27.2 %925 29.5 %1,360 Selling, general and administrative expenses509 31.8 %867 27.7 %1,376 Research and development expenses121 7.5 %282 9.0 %403 Other segment items(1)6 0.3 %6 0.2 %11 Segment operating income(2)528 33.1 %1,053 33.6 %1,582 Unallocated amounts:Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(232)Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs(209)Amortization expense(219)Operating income (loss) 921 Other income (expense), net(116)Income (loss) before income taxes$805 

28

Three Months Ended March 31, 2024MedSurg% of net salesCardiovascular% of net salesTotalNet sales of reportable segments$1,417 $2,458 $3,875 Impact of foreign currency fluctuations(19)Total net sales3,856 Segment expenses:Cost of products sold381 26.9 %811 33.0 %1,192 Selling, general and administrative expenses439 31.0 %740 30.1 %1,180 Research and development expenses107 7.6 %228 9.3 %335 Other segment items(1)5 0.3 %4 0.2 %9 Segment operating income(2)485 34.2 %674 27.4 %1,159 Unallocated amounts:Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments(146)Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits),